BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) will release its earnings data before the market opens on Monday, November 4th. Analysts expect BioCryst Pharmaceuticals to post earnings of ($0.07) per share for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.
BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.11. The firm had revenue of $109.30 million during the quarter, compared to analysts' expectations of $98.30 million. The business's revenue for the quarter was up 34.9% on a year-over-year basis. During the same period last year, the company earned ($0.24) earnings per share. On average, analysts expect BioCryst Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
BioCryst Pharmaceuticals Price Performance
Shares of NASDAQ BCRX traded up $0.20 during mid-day trading on Monday, reaching $8.15. The company's stock had a trading volume of 1,484,075 shares, compared to its average volume of 2,955,986. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $8.88. The firm has a market capitalization of $1.68 billion, a PE ratio of -7.64 and a beta of 1.88. The stock has a fifty day moving average of $7.83 and a two-hundred day moving average of $6.81.
Analysts Set New Price Targets
A number of equities analysts recently weighed in on BCRX shares. JMP Securities upped their target price on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a "market outperform" rating in a research report on Tuesday, August 6th. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. StockNews.com raised BioCryst Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Tuesday, August 6th. Barclays lifted their price objective on BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the stock an "equal weight" rating in a research note on Tuesday, August 6th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $14.17.
Check Out Our Latest Analysis on BCRX
About BioCryst Pharmaceuticals
(
Get Free Report)
BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
Further Reading
Before you consider BioCryst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.
While BioCryst Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
